Abstract
During the last decade there has been a growing interest towards the modulation of the cannabinoid CB1 receptor. The identification of CB1 cannabinoid receptor antagonists has been one of the major advances in cannabinoid research. Thus, the development of these ligands has opened new therapeutic applications. Since the discovery of the first cannabinoid receptor antagonist, rimonabant, by Sanofi in 1994, a large number of structural variations within this chemical series of 1,5-diarylpyrazoles have been described. So far, all attempts to identify novel structures for CB1 antagonists have been based on one or more pharmacophoric elements of the rimonabant structure. The advanced clinical trials of rimonabant confirm the therapeutic potential value of CB1 antagonists for the treatment of obesity. In addition, the results of pharmacological and clinical studies reveal other effective pharmacotherapeutic applications. The current review will mainly focus on the structure-activity relationships that have been established for antagonists/inverse agonists that bind to the CB1 cannabinoid receptors and on their therapeutic applications.
Keywords: Cannabinoid, antagonist, CB1, rimonabant, endocannabinoid
Current Topics in Medicinal Chemistry
Title: CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Volume: 8 Issue: 3
Author(s): Nadine Jagerovic, Cristina Fernandez-Fernandez and Pilar Goya
Affiliation:
Keywords: Cannabinoid, antagonist, CB1, rimonabant, endocannabinoid
Abstract: During the last decade there has been a growing interest towards the modulation of the cannabinoid CB1 receptor. The identification of CB1 cannabinoid receptor antagonists has been one of the major advances in cannabinoid research. Thus, the development of these ligands has opened new therapeutic applications. Since the discovery of the first cannabinoid receptor antagonist, rimonabant, by Sanofi in 1994, a large number of structural variations within this chemical series of 1,5-diarylpyrazoles have been described. So far, all attempts to identify novel structures for CB1 antagonists have been based on one or more pharmacophoric elements of the rimonabant structure. The advanced clinical trials of rimonabant confirm the therapeutic potential value of CB1 antagonists for the treatment of obesity. In addition, the results of pharmacological and clinical studies reveal other effective pharmacotherapeutic applications. The current review will mainly focus on the structure-activity relationships that have been established for antagonists/inverse agonists that bind to the CB1 cannabinoid receptors and on their therapeutic applications.
Export Options
About this article
Cite this article as:
Jagerovic Nadine, Fernandez-Fernandez Cristina and Goya Pilar, CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications, Current Topics in Medicinal Chemistry 2008; 8 (3) . https://dx.doi.org/10.2174/156802608783498050
DOI https://dx.doi.org/10.2174/156802608783498050 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Levosimendan: A Novel Agent in Heart Failure
Recent Patents on Cardiovascular Drug Discovery An Explicative Review on the Progress of Quinazoline Scaffold as Bioactive Agents in the Past Decade
Medicinal Chemistry Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders Effects of Remifentanil on the Cardiac Conduction System. Our Experience in the Study of Remifentanil Electrophysiological Properties
Current Pharmaceutical Design Hemothorax
Current Respiratory Medicine Reviews Red Wine, Arterial Stiffness and Central Hemodynamics
Current Pharmaceutical Design Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Recent Patents on Inflammation & Allergy Drug Discovery Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Drug Interactions of Tipranavir, a New HIV Protease Inhibitor
Drug Metabolism Letters Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Synthesis of Dihydropyridines: Patented Catalysts and Biological Applications
Recent Patents on Catalysis (Discontinued) Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Cardiovascular Effects Mediated by Imidazoline Drugs: An Update
Cardiovascular & Hematological Disorders-Drug Targets Stearoyl-CoA Desaturase: A Vital Checkpoint in the Development and Progression of Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology